These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19209136)

  • 1. Updates in anti-HER2 combination therapy.
    Burstein H
    Clin Adv Hematol Oncol; 2008 Dec; 6(12):873-4. PubMed ID: 19209136
    [No Abstract]   [Full Text] [Related]  

  • 2. [Chemotherapy for breast cancer refractory to anthracycline, taxane or trastuzumab].
    Ito Y; Kobayashi K
    Gan To Kagaku Ryoho; 2009 May; 36(5):726-9. PubMed ID: 19461171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotoxicities of breast cancer treatment.
    Viale PH; Yamamoto DS
    Oncology (Williston Park); 2009 Apr; 23(4 Suppl Nurse Ed):19-24. PubMed ID: 19856594
    [No Abstract]   [Full Text] [Related]  

  • 4. Breast cancer: Increasing therapy options for HER2-positive early breast cancer.
    Harbeck N
    Nat Rev Clin Oncol; 2011 Dec; 9(1):10-2. PubMed ID: 22186934
    [No Abstract]   [Full Text] [Related]  

  • 5. When an interim analysis of randomized trial changes the practice in oncology: the lesson of adjuvant Trastuzumab and the HERA trial.
    De Rossi C; Brunello A; Jirillo G; Jirillo A
    Immunopharmacol Immunotoxicol; 2009 Mar; 31(1):30-1. PubMed ID: 21054206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab.
    Jones LW; Haykowsky M; Peddle CJ; Joy AA; Pituskin EN; Tkachuk LM; Courneya KS; Slamon DJ; Mackey JR
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1026-31. PubMed ID: 17507633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Novel targeting therapy concept for breast cancer treatment].
    Toi M
    Nihon Yakurigaku Zasshi; 2008 Sep; 132(3):177-9. PubMed ID: 18787301
    [No Abstract]   [Full Text] [Related]  

  • 8. Trastuzumab as the lead monoclonal antibody in advanced breast cancer: choosing which patient and when.
    Olver IN
    Future Oncol; 2008 Feb; 4(1):125-31. PubMed ID: 18241007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer (metastatic).
    Stebbing J; Glassman R
    Clin Evid; 2005 Jun; (13):2197-225. PubMed ID: 16135325
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of adjuvant monoclonal antibody therapy for breast cancer: rationale and new studies.
    Perez EA
    Curr Oncol Rep; 2001 Nov; 3(6):516-22. PubMed ID: 11595120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
    Castrellon AB; Glück S
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug evaluation: Bay-59-8862.
    Eckstein JW
    IDrugs; 2004 Jun; 7(6):575-81. PubMed ID: 15197663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer.
    Yardley DA; Daniel D; Stipanov M; Drosick DR; Mainwaring M; Peyton J; Shastry M; Hainsworth JD
    Cancer Invest; 2010 Oct; 28(8):865-71. PubMed ID: 20690802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New molecule-targeting therapy with herceptin (trastuzumab), an anti-HER2 (c-erB-2) monoclonal antibody.
    Sakamoto G; Mitsuyama S
    Breast Cancer; 2000; 7(4):350-7. PubMed ID: 11114864
    [No Abstract]   [Full Text] [Related]  

  • 15. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
    Morris SR; Carey LA
    Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of trastuzumab alone therapy was compared to trastuzumab plus taxane therapy in patients of advanced and metastatic breast cancers].
    Sakurai K; Enomoto K; Kitajima A; Tani M; Amano S
    Gan To Kagaku Ryoho; 2007 Nov; 34(12):1911-3. PubMed ID: 18219850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drugs in breast cancer.
    Iqbal S; Miller WR
    Expert Opin Pharmacother; 2001 Jun; 2(6):975-85. PubMed ID: 11585013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
    Yao E; Zhou W; Lee-Hoeflich ST; Truong T; Haverty PM; Eastham-Anderson J; Lewin-Koh N; Gunter B; Belvin M; Murray LJ; Friedman LS; Sliwkowski MX; Hoeflich KP
    Clin Cancer Res; 2009 Jun; 15(12):4147-56. PubMed ID: 19509167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can HER2 status predict response to cancer therapy?
    Nelson NJ
    J Natl Cancer Inst; 2000 Mar; 92(5):366-7. PubMed ID: 10699062
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical implications of trastuzumab].
    Saeki T; Takashima S
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1094-9. PubMed ID: 12938263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.